ANDA 40557, held by Emerge Bioscience. Methylprednisolone Acetate.
As of Nov 20, 2026, ANDA 40557 (Methylprednisolone Acetate), held by Emerge Bioscience, was first approved by FDA on Feb 23, 2005, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 23, 2005 | Original application | Approved | None posted |
| Methylprednisolone Acetate40MG/ML · injectable;injection | Methylprednisolone Acetate | Rx |
| Methylprednisolone Acetate80MG/ML · injectable;injection | Methylprednisolone Acetate | Rx |
| Jul 6, 2022 | Supplement 34Labeling · Standard review | Approved | None posted |
| Aug 7, 2020 | Supplement 27Labeling · Standard review | Approved | None posted |
| Aug 7, 2020 | Supplement 30Labeling · Standard review | Approved | None posted |
| Jan 3, 2012 | Supplement 16Labeling | Approved | None posted |
| Dec 1, 2010 | Supplement 3Labeling | Approved | None posted |
| Feb 23, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters